Physician profile
Alan Stuart Weiss
NPI 1891710562
$9,429.24
in general payments reported to CMS, 2019-2025
58 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $856 · 2021: $1,504 · 2022: $1,926 · 2023: $1,535 · 2024: $1,549 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,501.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,367.91 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $917.13 | 2019-2025 | Vraylar, Qulipta |
| Novo Nordisk INC | $620.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $591.53 | 2022-2025 | Sunosi, Auvelity, Symbravo |
| Lilly USA, LLC | $429.07 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Lundbeck LLC | $401.41 | 2019-2024 | Rexulti |
| Pfizer INC. | $365.99 | 2019-2025 | |
| Horizon Therapeutics Plc | $319.04 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $252.87 | 2019-2023 | Rexulti |
| Csl Behring | $224.71 | 2019-2024 | Hizentra |
| Jazz Pharmaceuticals INC. | $218.20 | 2019-2023 | Xywav |
| Biohaven Pharmaceutical Holding Company LTD. | $186.25 | 2022 | |
| Acella Pharmaceuticals, LLC | $167.67 | 2022-2025 | NP Thyroid 60 |
| Ibsa Pharma INC. | $143.40 | 2019-2024 | Tirosint, Licart, Licart |
| Allergan, INC. | $142.00 | 2019-2020 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $141.62 | 2020-2025 | |
| Corium, LLC | $136.89 | 2022-2023 | Azstarys |
| Abbott Laboratories | $129.70 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Galderma Laboratories, L.P. | $120.54 | 2022 | |
| Antares Pharma, INC. | $90.50 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $89.67 | 2023-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $87.17 | 2021 | |
| Grifols USA, LLC | $83.87 | 2022-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Ironwood Pharmaceuticals, INC | $72.02 | 2020-2021 | |
| Corcept Therapeutics | $67.97 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $66.80 | 2019-2022 | |
| Almatica Pharma LLC | $66.74 | 2022-2023 | Loreev Xr |
| Gilead Sciences, INC. | $60.00 | 2024 | Biktarvy |
| Bausch Health US, LLC | $53.07 | 2021-2023 | Wellbutrin, Aplenzin |
| Mentor Worldwide LLC | $50.52 | 2022 | |
| Qol Medical, LLC | $49.76 | 2022-2023 | Sucraid |
| Adlon Therapeutics L.P. | $48.23 | 2019-2020 | |
| Exact Sciences Corporation | $47.08 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Harmony Biosciences LLC | $45.27 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $42.80 | 2020-2023 | Contrave |
| Phathom Pharmaceuticals, INC. | $38.17 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $37.74 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $36.01 | 2024-2025 | Strensiq |
| Janssen Biotech, INC. | $34.46 | 2019 | |
| Neos Therapeutics, LP | $34.13 | 2020 | |
| Supernus Pharmaceuticals, INC. | $30.38 | 2023-2024 | Qelbree, Qelbree |
| Dexcom, INC. | $27.79 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $26.33 | 2024 | |
| Alfasigma USA, INC. | $23.81 | 2022 | |
| Resmed Corp | $22.44 | 2024 | |
| Romark Laboratories, Lc | $20.36 | 2019 | |
| Therapeuticsmd, INC. | $20.24 | 2019 | |
| Acerus Pharmaceuticals Corporation | $18.60 | 2022 | |
| Phadia US INC. | $18.47 | 2019 | |
| Vyera Pharmaceuticals, LLC | $18.18 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.82 | 2019 | |
| Redhill Biopharma INC. | $16.66 | 2021 | |
| Tolmar, INC. | $16.63 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $15.71 | 2021 | |
| Avion Pharmaceuticals | $15.14 | 2022 | |
| Shire North American Group INC | $15.12 | 2019 | |
| Amgen INC. | $14.37 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.